• by bcarlson@marketresearch.com
  • November 7 2013


Biomarkers Market Exceeds 25 Billion

Biomarkers Market Exceeds 25 Billion

“Biomarkers like CK-MB have many positive benefits to medicine,” said our analyst Melissa Elder in a recent press release.  "Diseases are detected earlier, more effective treatments can be delivered, drug reactions reduced.”  The biomarker market is valued at $25.9 billion for 2013, an increase of 10.2% since last year, according to Elder’s report.   The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers).

Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging.  Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.  An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body’s tissues, and can suggest a cardiovascular event when levels are high.   

 

The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report.

The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America.  There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx.

Kalorama Information’s report, TheGlobal Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers) contains detailed breakouts of biomarker market segments, disease statistics and company profiles.   More information about the report can be obtained at Kalorama Information’s website: http://www.kaloramainformation.com/Global-Biomarkers-Cancer-7836984/